Tempus AI expands multi-year collaboration giving Gilead enterprise-wide access to Lens platform and multimodal real-world oncology data
Tempus AI expanded its multi-year Gilead collaboration on April 9, 2026, giving Gilead enterprise-wide access to the Lens platform and its 8.5M+ de-identified oncology records, plus dedicated Tempus analytical services. Financial terms were not disclosed. Selling analyst labour alongside the data keeps every step of the work inside Tempus.
Where the rake sits
Tempus keeps the full rake: substrate (8.5M+ records), tooling (Lens, Tempus One), and human analysts all sit inside Tempus' perimeter, and Gilead consumes rather than enriches. Financial split is not disclosed, so the size of the rake is not visible — but its ownership is.
What happened
- Deal announced as a multi-year expansion of an existing Tempus–Gilead collaboration, giving Gilead enterprise-wide access to the Lens platform.
- Lens bundles Tempus' multimodal oncology RWD library (8.5M+ de-identified patient records), AI compute, foundation models, and the Tempus One 'co-scientist' agent.
- Expanded scope explicitly adds dedicated Tempus analytical services on top of platform access.
- Gilead is scaling an oncology franchise (Trodelvy in 1L mTNBC; two additional cancer launches slated for 2026) that requires biomarker-defined cohorts beyond its internal trial data.
- Lens is already used by 19 of the top 20 biopharma, indicating a recurring licensing relationship rather than a one-off data sale.
- Financial terms not disclosed.
Who is involved
US precision-medicine company; owns Lens, an agentic AI platform built on a multimodal library of 8.5M+ de-identified oncology patient records that biopharma uses for trial design and biomarker work.
FY2025 revenue $1.27B (up 83% YoY); NASDAQ: TEM
US biopharma (HIV, hepatitis, oncology via Trodelvy/Cell Therapy); sits on the buyer side, using external RWD/AI platforms to accelerate its oncology pipeline.
FY2025 revenue $29.4B; Nasdaq: GILD
The reading
Enrichment sits inside Tempus' perimeter: Tempus curates the 8.5M+ de-identified multimodal records, runs the Lens agentic platform, and - per the expansion - layers in 'dedicated Tempus analytical services' alongside enterprise-wide Lens access for Gilead.
The substrate's value to Gilead is that it feeds concrete R&D decisions - which trial to design, which biomarker-defined patient subgroup to enrol, which indication to prioritise across Gilead's oncology portfolio - against a longitudinal real-world dataset Gilead cannot assemble itself.
The underlying de-identified patient records and foundation models do not cross to Gilead; what crosses is enterprise-wide access to query them inside Lens plus the outputs of Tempus analytical services. Per the author's Tempus/Gilead ruling, in-place access through a platform is still a sale when the dataset and its analysis are the deliverable - this is not a wrap.
Not determinable from public facts: deal value, duration and whether pricing is seat-based, consumption-based or milestone-tied were not disclosed in the April 2026 announcement.
Why it matters
The addition worth noticing is not the enterprise licence, it is the dedicated analytical services. Tempus is now selling labour alongside substrate, which is where a rake becomes genuinely defensible and also where it stops scaling like software. Every data business that runs out of pricing power on the asset eventually makes this move.
The argument this deal tests: The rake is decided before the negotiation begins
Related deals
- Tempus expands multi-year Merck collaboration giving Merck access to de-identified multimodal data and Lens platform2026-03-03
- Owkin licenses K Pro AI scientist and MOSAIC multimodal patient data to Servier for oncology research2026-09-11
- Owkin licenses K Pro AI Scientist plus multimodal oncology and immunology patient data to Boehringer Ingelheim2026-09-02
- Flatiron Health renews NCCN real-world oncology data collaboration through 2028, deploys Flatiron Telescope2026-09-09
Sources
- investors.tempus.com — primary
- stockanalysis.com — party background
- businesswire.com — party background
- gilead.com — party background
- macrotrends.net — party background
Announced 2026-04-09 (date uncertain)